Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2295 | Desmethoxy yangonin |
| Desmethoxyyangonin is a reversible inhibitor of MAO-B, it may have important therapeutic value for treatment of neurodegenerative disorders and Parkinson's Disease. Desmethoxy yangonin protects LPS or LPS/D-GalN-induced damages in cell or liver tissues mainly through de-regulating IKK/NFκB and Jak2/STAT3 signaling pathways. | |
| BCN2297 | Bufarenogin |
| 1. ψ-Bufarenogin exhibits potent therapeutic effect in xenografted human hepatoma without notable side effects,at least partially,via inhibiting receptor tyrosine kinases-regulated signaling. 2. ψ-Bufarenogin has inhibitory activity on human kidney Na(+)/K(+)-ATPase. 3. ψ-Bufarenogin has cytotoxicity against HepG2 and MCF-7 human cancer cells. | |
| BCN2298 | 11-Keto-beta-boswellic acid |
| 11-Keto-beta-boswellic acid, a novel Nrf2 activator, and a selective 5-lipoxygenase (5-LOX) inhibitor; it exerts dose dependent cardioprotective effect manifested by dose-dependent reduction in serum lactate dehydrogenase; and it can increase the Nrf2 and HO-1 expression, which provides protection against oxygen and glucose deprivation (OGD)-induced oxidative insult. 11-Keto-beta-boswellic acid possesses significant anti-inflammatory, and anti-tumoral activities. | |
| BCN2306 | Methysticin |
| 1. Methysticin and yangonin show in vitro hepatotoxicity on human hepatocytes (HepG2) . 2. Methysticin and 7,8-dihydroMethysticin contribute to CYP1A1 induction. 3. Methysticin is a potent NF-kappaB inhibitor in kava with minimum toxicity. 4. Methysticin possesses anticonvulsant and neuroprotective properties, possibly by interfering with frequency potentiation. | |
| BCN2308 | Dihydroisotanshinone I |
| Dihydroisotanshinone I has protective action against menadione-induced hepatotoxicity, attributed to its antioxidant properties including the free radical scavenging activity and inhibition of lipid peroxidation. | |
